Skip to main content

Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion

The Original Article was published on 19 August 2021

Correction to: Trials 22, 550 (2021)

https://doi.org/10.1186/s13063-021-05461-9

Following the publication of the original article [1], we were notified that the Flu-iiQ™ table included in the supplementary material of original publication needs to be deleted. The authors were not at liberty to publish the table in full as a number of the items listed are confidential and commercially sensitive. For full details of the Flu-iiQ™ questionnaire please contact Measured Solutions P/L, PO Box 5127, Alphington VIC 3079, Australia (measuredsolutions.com.au).

The original article has been corrected.

Reference

  1. Halford, et al. SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion. Trials. 2021;22:550. https://doi.org/10.1186/s13063-021-05461-9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Sarah Halford.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Halford, S., Wan, S., Dragoni, I. et al. Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion. Trials 23, 336 (2022). https://doi.org/10.1186/s13063-022-06266-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13063-022-06266-0